Nutriband Inc. and Kindeva Scale Up Commercial Manufacturing of Aversa Fentanyl, Pioneering Abuse-Deterrent Opioid Patch

The collaboration between Nutriband Inc. (NASDAQ: NTRB) and Kindeva has reached a pivotal milestone with the successful scale-up of the commercial manufacturing process for Aversa Fentanyl. This development is not just a technical achievement but a beacon of hope in the ongoing battle against opioid abuse. Aversa Fentanyl, which combines Nutriband's AVERSA abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, is poised to become the world's first abuse-deterrent opioid patch. The significance of this advancement cannot be overstated, given the global opioid crisis that has claimed countless lives and devastated communities.

The next phase for Nutriband and Kindeva involves producing clinical supplies and submitting an Investigational New Drug application to initiate a human abuse liability study. This study is crucial for understanding how Aversa Fentanyl performs in real-world scenarios, particularly its effectiveness in deterring abuse. The potential impact of Aversa Fentanyl is immense, with Nutriband projecting peak U.S. sales between $80 million and $200 million. Beyond financial success, the broader implications for public health and safety are profound. By integrating abuse-deterrent technology into a transdermal patch, Aversa Fentanyl could significantly reduce the rates of misuse, diversion, and accidental exposure associated with opioids.

The global ambitions of Aversa Fentanyl are supported by Nutriband's extensive international patent portfolio, underscoring the universal need for safer opioid alternatives. This development represents a critical step forward in pharmaceutical innovation, offering a glimmer of hope in addressing one of the most pressing public health challenges of our time. The collaboration between Nutriband and Kindeva exemplifies how strategic partnerships can accelerate the development of solutions that have the potential to save lives and reshape the future of pain management.